arrow
R

Rea, Giuseppina

istituto nazionale tumori
H指数:0
被引数:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells

CXCR4、CXCR7和PBRM1是人类肾癌细胞中依维莫司和卡博赞尼耐药性的相关因素。

2026-03-280
OAAI
Comprehensive structural investigation of a potent and selective CXCR4 antagonist via crosslink modification
2024-12-010
PRE
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024-08-211
OAAI
CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization
HELIYON
IF3.6
2024-08-010
OAAI
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients
2024-05-042
OA
CXCL12-loaded-hydrogel (CLG) in vivo modifies lung metastatic niche toward an immunoactive microenvironment reducing lung metastasis development
2024-03-220
PRE
Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study

来自胃肠道的寡转移肿瘤: 临床和分子驱动因素的鉴定: 预测研究

2023-10-190
OAAI
In PD-1+human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies
2022-03-0432
OAAI
Disulfide Bond Replacement with 1,4-and 1,5-Disubstituted [1,2,3]-Triazole on C-X-C Chemokine Receptor Type 4 (CXCR4) Peptide Ligands: Small Changes that Make Big Differences
2020-07-2014
PREAI
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

靶向CXCR4增强anti-PD-1改善肿瘤微环境和抑制肿瘤PD-1的功效

2019-10-2880
OAAI
Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity

突变的Von hippel-lindau肾细胞癌 (RCC) 促进患者特异性自然杀伤 (NK) 细胞毒性

2018-12-0414
OAAI